Deregulation of the KIT receptor TK by the prevalent activation loop mutation D816V has served as a focal point in therapeutic strategies aimed curbing neoplastic mast cell growth. Perhaps the most important development in this era of targeted therapy, and certainly relevant to KIT-driven diseases ...
PV6201 KIT D816V 1 mg 83981 1 mg Thermo-life PV6210 MET D1228H 1 mg 83981 1 mg Thermo-life PV6216 RET G691S 1 mg 83981 1 mg Thermo-life PV6225 RET V804M 1 mg 83981 1 mg Thermo-life PV6228 TEK (TIE2) R849W 1 mg 83981 1 mg Thermo-life PV6231 TEK (TIE2) Y1108F 1 ...
However, it is also inactive or significantly less active against certain other mutant forms of KIT, for example the D816V mutation commonly found in systemic mastocytosis. The present invention is based upon research that correlates the treatment of a disease characterized by a mutant form of ...
For example, regorafenib was more active against KIT exon 17 D816E mutation than D816H. Other KIT oncogenic mutations, including an exon 13 K642E primary mutation, and the exon 14 T670I “gatekeeper” secondary mutation, were inhibited effectively by both sunitinib and regorafenib.32,33 Very...
deregulation of the KIT receptor TK by the prevalent activation loop mutation D816V has served as a focal point in therapeutic strategies aimed at curbing neoplastic mast cell growth. c-Kit is expressed in hematopoietic stem cells, germ cells, mast cells and gastrointestinal tract cajal cells. Up...
deregulation of the KIT receptor TK by the prevalent activation loop mutation D816V has served as a focal point in therapeutic strategies aimed at curbing neoplastic mast cell growth. c-Kit is expressed in hematopoietic stem cells, germ cells, mast cells and gastrointestinal tract cajal cells...